Figure 5

Tasquinimod blocks the angiogenic switch in CWR-22RH tumors. Inhibition of the "angiogenic switch" was illustrated in treated CWR-22RH tumors. (A) Tumor growth reduction of CWR-22RH human prostate tumors inoculated into nude mice after oral treatment with tasquinimod at 10 mg/kg/day, data points represent the average ± SD, (n = 5, (**) p = 0.002; Mann-Whitney U). (B) Reduced tumor levels of VEGF, a downstream HIF1α target gene. Bars represent the mean ± SD, n = 5 and (*) p < 0.05. (C) The up-regulation of TSP1 (mouse monoclonal Ab11) in tumor tissue excised and prepared as whole cell lysates (10,000 g supernatant) was accompanied with a down-regulation of the androgen receptor (AR), HIF1α, and Glut-1. (i) Each lane represents a tumor sample from an individual animal (#11 to #15 controls and #21 to #25 exposed to tasquinimod). Molecular weight markers for each blot are indicated. (ii) Calculated ratios between the major protein bands and actin for each lane show a statistical significant difference between exposed animals (#T21 - #T25) compared to untreated controls (#T11-#T15). (*) p ≤ 0.05, (**) p ≤ 0.01 and (***) p ≤ 0.001 (Bonferroni's multiple comparison test).